Impact of Chloroprocaine (CLOROTEKAL®) on Eligibility for Discharge From Hospital After Outpatient Surgery

Nordic Pharma SAS620 enrolled

Overview

The purpose of this study is to assess, in real life, the efficacy and the eligibility for discharge of a local anesthetic, CLOROTEKAL®, used for spinal anesthesia in short outpatient surgery.

This is a longitudinal, observational, prospective, multicentre, national study, conducted in France, from a representative sample of physician anesthetists. The efficacy and safety in real life of CLOROTEKAL® will be assessed in patients undergoing a short outpatient surgery under spinal anesthesia. Data will be collected by the physician during two visits (pre-anesthesia and per-postoperative consultation). Additional data regarding the patient's perception (safety, pain and satisfaction) will be collected using a self-questionnaire.

Study Type

OBSERVATIONAL

Enrollment

620

Conditions

Spinal Anesthesia Outpatient Surgery

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients seen in pre-anesthesia consultation for ambulatory surgery * Patients for whom a spinal anesthesia using CLOROTEKAL® is planned * Patients accepting and able to complete a satisfaction self-administered questionnaire * Informed patients who accept the computer processing of their medical data and their right of access and correction Exclusion Criteria: * Patients with contra-indications to spinal anesthesia (eg decompensated cardiac insufficiency, hypovolemic shock….) * Patients with contra-indications to chloroprocaine (hypersensitivity to the active substance, medicinal products of the para-aminobenzoic acid ester group, other ester-type local anaesthetics or to any of the excipients ; Intravenous regional anaesthesia (the anesthetic agent is introduced into the limb and allowed to set in while tourniquets retain the agent within the desired area), serious problems with cardiac conduction, severe anemia) * Patients participating or having participated in the previous month in a clinical trial in anesthesiology

Locations (1)

Nordic Pharma

Paris, France

Outcomes

Primary Outcomes

Impact of CLOROTEKAL® on the discharge from hospital

Time to eligibility for discharge from hospital measured as the time between the intrathecal injection and achieving the criteria of Lacasse. This period will be described globally (average time) and by groups: \<180 min ; \<240 min ; \<300 min ; \<360 min ; \> 360 min.

Time frame: Average time expected around 180 min after the surgery (Lacasse, 2011)

Secondary Outcomes

Modalities of spinal anesthesia with CLOROTEKAL®

Time frame: During surgery

Safety of CLOROTEKAL

Percentage and nature of adverse effect (serious or not) after intrathecal anaesthesia with chloroprocaine.

Time frame: Up to 24 hours after surgery

Patients' satisfaction

Time frame: 24h after surgery

Postoperative patients pain

Time frame: During the 24 hours following surgery

Rate of unplanned admissions related to anesthesia and/or surgery

Time frame: Within the same day than surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.